Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 24  •  10:27AM ET
9.10
Dollar change
-0.36
Percentage change
-3.75
%
Index- P/E- EPS (ttm)-10.26 Insider Own27.96% Shs Outstand3.82M Perf Week9.96%
Market Cap34.78M Forward P/E- EPS next Y-3.68 Insider Trans0.00% Shs Float2.75M Perf Month46.85%
Enterprise Value29.90M PEG- EPS next Q-1.00 Inst Own1.78% Short Float4.44% Perf Quarter-46.66%
Income-28.51M P/S- EPS this Y38.19% Inst Trans5.26% Short Ratio1.07 Perf Half Y-56.89%
Sales0.00M P/B4.02 EPS next Y54.62% ROA-171.84% Short Interest0.12M Perf YTD147.42%
Book/sh2.27 P/C5.53 EPS next 5Y- ROE-228.60% 52W High38.25 -76.20% Perf Year203.50%
Cash/sh1.65 P/FCF- EPS past 3/5Y-131.29% -17.64% ROIC-329.51% 52W Low2.89 215.05% Perf 3Y-83.12%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility11.25% 15.26% Perf 5Y-92.26%
Dividend TTM- EV/Sales- EPS Y/Y TTM-136.69% Oper. Margin- ATR (14)1.23 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.39 Sales Y/Y TTM- Profit Margin- RSI (14)48.09 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio1.41 EPS Q/Q66.44% SMA20-4.98% Beta0.21 Target Price45.00
Payout- Debt/Eq0.30 Sales Q/Q- SMA50-9.44% Rel Volume0.68 Prev Close9.46
Employees7 LT Debt/Eq0.00 EarningsNov 07 BMO SMA200-34.62% Avg Volume114.23K Price9.10
IPOJun 08, 2018 Option/ShortNo / Yes EPS/Sales Surpr.53.53% -100.00% Trades Volume14,635 Change-3.75%
Dec-23-25 08:00AM
Dec-22-25 07:00AM
Dec-19-25 04:52PM
Dec-10-25 08:00PM
Dec-01-25 07:00AM
09:30AM Loading…
Nov-28-25 09:30AM
Nov-27-25 04:00PM
Nov-26-25 09:30AM
Nov-25-25 04:00PM
Nov-07-25 07:00AM
Oct-31-25 07:51PM
Oct-29-25 09:00PM
Oct-23-25 08:15AM
Oct-20-25 08:30AM
Oct-14-25 08:15AM
08:00AM Loading…
Oct-08-25 08:00AM
Oct-07-25 11:00AM
Oct-03-25 07:00AM
Oct-02-25 07:57AM
Oct-01-25 07:50AM
Sep-29-25 07:40AM
Sep-26-25 08:00PM
Sep-24-25 08:30AM
Sep-18-25 08:10AM
Sep-12-25 07:50AM
Sep-10-25 07:00AM
Aug-21-25 07:00AM
Aug-11-25 06:32PM
07:40AM
Aug-08-25 08:00AM
07:00AM Loading…
Aug-07-25 07:00AM
Aug-05-25 07:34AM
Aug-04-25 07:33AM
Jul-31-25 07:24AM
Jul-22-25 07:00AM
Jul-08-25 08:00AM
Jun-27-25 04:30PM
04:30PM
Jun-26-25 07:30AM
Jun-18-25 09:19AM
Jun-17-25 08:00AM
Jun-13-25 07:00AM
Jun-10-25 08:00AM
Jun-03-25 07:50AM
May-30-25 07:00AM
May-29-25 07:30AM
May-28-25 08:00AM
May-21-25 08:00AM
May-20-25 08:00AM
07:30AM
May-19-25 07:30AM
May-16-25 07:30AM
May-12-25 08:00AM
May-05-25 07:08AM
Apr-24-25 07:00AM
Apr-22-25 07:00AM
Apr-18-25 04:00PM
Apr-14-25 07:30AM
Apr-10-25 07:30AM
Apr-03-25 07:00AM
Apr-01-25 02:00AM
Mar-31-25 07:00AM
Mar-30-25 07:00PM
Mar-28-25 09:15AM
Mar-27-25 07:00AM
Mar-26-25 07:00AM
Mar-20-25 08:09AM
07:30AM
Mar-17-25 11:33AM
Mar-07-25 03:00PM
Feb-28-25 11:30AM
Feb-26-25 07:30AM
Feb-18-25 07:30AM
Feb-11-25 07:30AM
Feb-10-25 07:30AM
Feb-06-25 07:30AM
Feb-04-25 08:00AM
07:03AM
Jan-17-25 07:30AM
Jan-14-25 08:30AM
Jan-07-25 08:30AM
Dec-20-24 07:30PM
09:15AM
Dec-13-24 07:00PM
Dec-10-24 07:30AM
Dec-05-24 07:30AM
Nov-25-24 07:00AM
Oct-29-24 07:30AM
Oct-28-24 11:10AM
Oct-23-24 09:30AM
Oct-22-24 07:00AM
Oct-21-24 11:55AM
07:00AM
05:30AM
Oct-15-24 06:00AM
Oct-07-24 08:40AM
Sep-27-24 08:06PM
Sep-25-24 09:20AM
Sep-13-24 04:00PM
Sep-09-24 07:30AM
Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.